Incidence and clinical significance of adrenal masses in patients with gastrenteropancreatic neuroendocrine tumors Abstract #59

Introduction: The widespread application of modern imaging modalities, mainly computerized tomography (CT) and magnetic resonance imaging (MRI), has revealed a 2-3% incidence of inadvertently discovered adrenal masses, the majority of which are non-functioning benign adrenal adenomas. In the presence of a known malignancy, such lesions have a more than 30% incidence of being metastases. As patients with gastrenteropancreatic neuroendocrine tumors (GEP-NETS) have mainly well-differentiated and slow-growing tumors and are subject to routine abdominal imaging for disease staging or during follow-up, it is important to study the incidence and significance of such lesions based on the recently introduced TNM classification system.
Aim(s): To determine the incidence, character and follow-up of adrenal masses revealed by imaging in patients with various GEP-NETS and to relate them to clinical, biochemical, histopathological parameters.
Materials and methods: We retrospectively studied 115 patients with GEP-NETS (2005-2009) and recorded: gender, age at diagnosis, size and location of the primary tumor, stage and grading of the disease. Abdominal imaging was then evaluated for the presence of adrenal abnormalities, and monitored during the course of the disease and follow-up period (mean) by functional status assessment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Georgios Kanakis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#114 Downstaging of a gastroenteropancreatic neuroendocrine tumor after combination therapy of temozolomide, Bevacizumab and long-acting somatostatin analogs
Introduction: Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Stavroula Antoniou
#214 Comparison of the AJCC and ENETS Staging Classifications for Neuroendocrine Tumors of the Pancreas
Introduction: The AJCC Cancer Staging Manual (7th edition, 2010) has introduced a novel TNM staging classification for pancreatic NETs. This classification has not yet been validated.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
Authors: Strosberg J, Cheema A, Weber J, Kvols L, ...
#531 Long-Term Outcomes in 50 Consecutive Patients with Neuroendocrine Tumors of the Pancreas
Introduction: Recently, the new World Health Organization (WHO) classification and TNM staging for neuroendocrine tumors of the pancreas (pNETs) were published.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Takeshi Natori
Authors: Natori T, Katori M, Seki M, ...
#627 Pancreatic Neuroendocrine Tumors: Two Different TNM Staging Systems
Introduction: Several staging systems for pancreatic neuroendocrine tumors (PNETs) exist but the most appropriate one has not been defined.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: Elena Martin-Perez
#580 Diagnostic Performance of Dual Tracer PET/CT in Staging Neuroendocrine Tumors of the Lung
Introduction: Different positron emission tomography/computed tomography (PET/CT) tracers may be useful in staging lung neuroendocrine tumors (LNETs)
Conference:
Category: Clinical
Presenting Author: Dr. Giorgio Treglia
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.